Stockscreener 앱 받기
5.33
3.09%
-0.17
시간 외 거래:
5.23
-0.10
-1.88%
전일 마감가:
$5.50
열려 있는:
$5.49
하루 거래량:
69,382
Relative Volume:
0.46
시가총액:
$54.12M
수익:
$52.29M
순이익/손실:
$-73.52M
주가수익비율:
-8.0758
EPS:
-0.66
순현금흐름:
$-100.45M
1주 성능:
+6.18%
1개월 성능:
+4.72%
6개월 성능:
-36.32%
1년 성능:
-45.16%
1일 변동 폭
$5.16
$5.6761
1주일 범위
$4.95
$5.75
52주 변동 폭
$3.61
$13.44
Precision Biosciences Inc Stock (DTIL) Company Profile
명칭
Precision Biosciences Inc
전화
919-314-5512
주소
302 EAST PETTIGREW STREET, DURHAM, NC
DTIL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DTIL
Precision Biosciences Inc
|
5.33 | 54.12M | 52.29M | -73.52M | -100.45M | -0.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-10 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2024-04-30 | 개시 | Guggenheim | Buy |
| 2022-06-17 | 개시 | BMO Capital Markets | Outperform |
| 2022-06-09 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2020-07-27 | 재개 | BTIG Research | Buy |
| 2020-04-03 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-03-05 | 개시 | Stifel | Buy |
| 2020-02-25 | 개시 | William Blair | Outperform |
| 2019-08-09 | 개시 | BTIG Research | Buy |
| 2019-07-16 | 개시 | H.C. Wainwright | Buy |
| 2019-04-22 | 개시 | Barclays | Overweight |
| 2019-04-22 | 개시 | Goldman | Buy |
| 2019-04-22 | 개시 | JP Morgan | Overweight |
| 2019-04-22 | 개시 | Jefferies | Buy |
모두보기
Precision Biosciences Inc 주식(DTIL)의 최신 뉴스
Trading (DTIL) With Integrated Risk Controls - news.stocktradersdaily.com
DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock Up - TradingView
Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B | DTIL Stock News - GuruFocus
FDA fast tracks Precision BioSciences’ hepatitis B treatment By Investing.com - Investing.com South Africa
Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B - BioSpace
Precision BioSciences stock rises following FDA Fast Track designation By Investing.com - Investing.com India
Precision BioSciences Gets FDA Fast Track Label for PBGENE-HBV - marketscreener.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
FDA Fast Tracks Precision BioSciences' (DTIL) Hepatitis B Gene E - GuruFocus
FDA fast tracks Precision BioSciences’ hepatitis B treatment - Investing.com Australia
Precision BioSciences stock rises following FDA Fast Track designation - Investing.com Australia
FDA Fast Tracks Precision BioSciences' (DTIL) Hepatitis B Gene Editing Program | DTIL Stock News - GuruFocus
Precision Biosciences Receives U.S. FDA Fast Track Designation For Pbgene-Hbv - marketscreener.com
Revolutionary Gene Editing Treatment for Hepatitis B Wins FDA Fast Track Status - Stock Titan
SEC Form PRE 14A filed by Precision BioSciences Inc. - Quantisnow
Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference - 01net
Gene Editing Pioneer Precision BioSciences Reveals Latest ARCUS Platform Progress at Major Healthcare Conference - Stock Titan
Precision Biosciences director Kevin Buehler buys $21,122 in stock - Investing.com Australia
Precision Biosciences director Melinda Brown buys $8,735 in stock By Investing.com - Investing.com South Africa
Precision Biosciences director Melinda Brown buys $8,735 in stock - Investing.com India
Precision Biosciences director Kevin Buehler buys $21,122 in stock By Investing.com - Investing.com UK
Precision BioSciences (DTIL) Reports Q4 Loss, Misses Revenue Estimates - MSN
Precision Biosciences director Germano Geno J purchases $17,225 in stock By Investing.com - Investing.com Australia
Precision Biosciences director Germano Geno J purchases $17,225 in stock - Investing.com India
Precision BioSciences: Q4 Earnings Snapshot - Big Rapids Pioneer
Precision BioSciences Reports Positive 2024 Financial Results - TipRanks
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update - CRISPR Medicine News
Precision BioSciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
PRECISION BIOSCIENCES Earnings Results: $DTIL Reports Quarterly Earnings - Nasdaq
Precision Biosciences Reports Fourth Quarter And FY 2024 Results - MarketScreener
Precision BioSciences Inc Q4 Sales Decline - Nasdaq
Precision Biosciences CEO sells $5,359 in stock By Investing.com - Investing.com Australia
Precision Biosciences CEO sells $5,359 in stock - Investing.com India
Character Biosciences Raises $93 Million Series B to Advance Precision Medicine for Progressive Eye Diseases - Business Wire
PRECISION BIOSCIENCES Earnings Preview: Recent $DTIL Insider Trading, Hedge Fund Activity, and More - Nasdaq
Gene Editing Tools Market Growth Demand, Segment Analysis - openPR.com
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025 - BioSpace
Precision Biosciences Inc (DTIL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
36.06%
자본화:
|
볼륨(24시간):